They verified that only prostate cancers expressing both PSCA and PSMA antigens are destroyed by these modified T cells, while single-antigen-positive tumours are not [93], ensuring enhanced specificity and safety in CAR-T cell activation. Here, FOLH1 is linked to prostate carcinoma.